IL142255A0 - Method of treating heparin-induced thrombocytopenia - Google Patents

Method of treating heparin-induced thrombocytopenia

Info

Publication number
IL142255A0
IL142255A0 IL14225599A IL14225599A IL142255A0 IL 142255 A0 IL142255 A0 IL 142255A0 IL 14225599 A IL14225599 A IL 14225599A IL 14225599 A IL14225599 A IL 14225599A IL 142255 A0 IL142255 A0 IL 142255A0
Authority
IL
Israel
Prior art keywords
induced thrombocytopenia
heparin
provides
treating heparin
treating
Prior art date
Application number
IL14225599A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL142255A0 publication Critical patent/IL142255A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL14225599A 1998-11-13 1999-11-10 Method of treating heparin-induced thrombocytopenia IL142255A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10843298P 1998-11-13 1998-11-13
PCT/US1999/026770 WO2000029014A1 (en) 1998-11-13 1999-11-10 Method of treating heparin-induced thrombocytopenia

Publications (1)

Publication Number Publication Date
IL142255A0 true IL142255A0 (en) 2002-03-10

Family

ID=22322154

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14225599A IL142255A0 (en) 1998-11-13 1999-11-10 Method of treating heparin-induced thrombocytopenia

Country Status (13)

Country Link
US (1) US6743426B2 (es)
EP (1) EP1128842B1 (es)
JP (1) JP2002529515A (es)
CN (1) CN1326355A (es)
AT (1) ATE320263T1 (es)
AU (1) AU1477000A (es)
BR (1) BR9915317A (es)
CA (1) CA2351067A1 (es)
DE (1) DE69930419T2 (es)
ES (1) ES2259248T3 (es)
IL (1) IL142255A0 (es)
WO (1) WO2000029014A1 (es)
ZA (1) ZA200102722B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468358B2 (en) * 2004-06-16 2008-12-23 Paringenix, Inc. Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome
US20090054374A1 (en) * 2007-02-28 2009-02-26 Paringenix, Inc. Methods of treating acute exacerbations of chronic obstructive pulmonary disease
JP2010534672A (ja) * 2007-07-23 2010-11-11 ユニバーシティ オブ ユタ リサーチ ファウンデーション 終末糖化産物受容体（ｒａｇｅ）の連結を阻止するための方法
KR102452803B1 (ko) 2012-05-09 2022-10-07 캔텍스 파마슈티칼즈, 인크. 골수억제의 치료
WO2016133910A1 (en) 2015-02-17 2016-08-25 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US5550036A (en) 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
US4992373A (en) 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
IL97312A (en) 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5270178A (en) * 1990-02-23 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
US5831141A (en) * 1991-01-11 1998-11-03 United States Of America As Represented By The Department Of Health And Human Services Expression of a heterologous polypeptide in mammary tissue of transgenic non-human mammals using a long whey acidic protein promoter
JPH06507307A (ja) 1991-01-11 1994-08-25 アメリカン・レツド・クロス トランスジェニック動物の乳腺組織における活性ヒトプロテインｃの発現
AT402262B (de) 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
JPH05271098A (ja) * 1992-03-26 1993-10-19 Teijin Ltd 活性化プロテインｃを有効成分とする抗血小板剤
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
ID23176A (id) * 1997-03-24 2000-03-23 Lilly Co Eli Metoda untuk mengobati gangguan pembuluh darah
US6159468A (en) * 1997-04-28 2000-12-12 Eli Lilly And Company Activated protein C formulations
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders

Also Published As

Publication number Publication date
CA2351067A1 (en) 2000-05-25
US20010018050A1 (en) 2001-08-30
BR9915317A (pt) 2001-08-07
EP1128842A1 (en) 2001-09-05
DE69930419D1 (de) 2006-05-11
WO2000029014A1 (en) 2000-05-25
DE69930419T2 (de) 2006-09-07
ZA200102722B (en) 2002-05-03
AU1477000A (en) 2000-06-05
JP2002529515A (ja) 2002-09-10
EP1128842B1 (en) 2006-03-15
US6743426B2 (en) 2004-06-01
ES2259248T3 (es) 2006-09-16
CN1326355A (zh) 2001-12-12
ATE320263T1 (de) 2006-04-15

Similar Documents

Publication Publication Date Title
DE69626660D1 (en) 2-alkylpyrrolidine
SI0817627T1 (es)
GR3037074T3 (en) Protein kinase c inhibitors
BG103671A (en) Combinations of sulphonylcarbamide-glytazone having synergetic effect for the treatment of diabetes
MY130580A (en) Oxalylamino-benzofuran and benzothienyl derivatives
AU7585598A (en) Raf kinase inhibitors
GB2368796A (en) Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
BR9610838A (pt) Processo para tratar um indivìduo tendo uma condição patológica envolvendo neovascularização.
IL156584A0 (en) Substituted triazole diamine derivatives as kinase inhibitors
BG102644A (en) Improved concentrated inoculation and infusion solutions for intravasal application
CA2301032A1 (en) A method of preventing or treating estrogen-dependent diseases and disorders
BG102259A (en) Compostions with controlled paroxetine release
AU5553296A (en) Arteriovenous and venous graft treatments: methods and compositions
IL142220A0 (en) Method of treating viral hemorrhagic fever
WO2000021513A3 (en) Methods for treating multiple sclerosis
MX9605072A (es) Dispositivo dispensador para pretratamiento.
IL142255A0 (en) Method of treating heparin-induced thrombocytopenia
HU9700024D0 (en) Imidazopyridin-azolidinones
IL142247A0 (en) Method of treating sickle cell disease and thalassemia
IL142249A0 (en) Method of treating thrombocytopenic purpura and hemolytic uremic syndrome
CA2294243A1 (en) Novel cyanoaziridines for treating cancer
UA42749C2 (uk) N,n-діетил-8,8-дипропіл-2-азаспіро[4,5]декан-2-пропанамін дималеат, фармацевтична композиція, спосіб лікування
EP0646651A3 (en) Method for improving the treatment of leather.
AU1278700A (en) Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline
UA15363A (uk) Засіб для лікуваhhя відкритих пошкоджеhь